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This uncontrolled prospective cohort study evaluated the use of accelerated resolution ther-
apy (ART) for treatment of comorbid symptoms of post-traumatic stress disorder (PTSD)
and major depressive disorder. Twenty-eight adult subjects, mean age of 41 years (79%
female, 36% Hispanic), received a mean of 3.7±1.1 ART treatment sessions (range 1–5).
ART is a new exposure-based psychotherapy that makes use of eye movements. Subjects
completed a range of self-report psychological measures before and after treatment with
ART including the 17-item PCL-C checklist (symptoms of PTSD) and 20-item Center for Epi-
demiologic Studies Depression Scale (CES-D). For the PCL-C, the pre-ART mean (±standard
deviation) was 62.5 (8.8) with mean reductions of −29.6 (12.5), −30.1 (13.1), and −31.4
(14.04) at post-ART, 2-month, and 4-month follow-up, respectively (p<0.0001 for compar-
isons to pre-ART score). Compared to pre-ART status, this corresponded to standardized
effect sizes of 2.37, 2.30, and 3.01, respectively. For the CES-D, the pre-ART mean was
35.1 (8.8) with mean reductions of −20.6 (11.0), −18.1 (11.5), and −15.6 (14.4) at post-ART,
2-month, and 4-month follow-up, respectively (p≤0.0001 compared to Pre-ART score).
This corresponded to standardized effect sizes of 1.88, 1.58, and 1.09, respectively. Strong
correlations were observed at 2-month and 4-month follow-up for post-treatment changes
in PTSD and depression symptom scores (r =0.79, r =0.76, respectively, p≤0.0002). No
serious treatment-related adverse effects were reported. In summary, ART appears to be a
promising brief, safe, and effective treatment for adults with clinically significant comorbid
symptoms of PTSD and depression. Future controlled and mechanistic studies with this
emerging therapy are warranted, particularly given its short treatment duration, and in light
of current heightened emphasis on health care cost constraints.
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INTRODUCTION
Post-traumatic stress disorder (PTSD) is a prevalent, disabling
anxiety disorder characterized by re-experiencing, avoidance,
numbing, or arousal that may occur after witnessing or experienc-
ing a traumatic event (American Psychiatric Association, 2000).
The lifetime prevalence of PTSD among adults in the U.S. has
been estimated at 6.8% (Kessler et al., 2005). PTSD is often com-
pounded by comorbid diagnoses of other mood disorders, par-
ticularly depression. Data from the National Comorbidity Survey
estimate a correlation between lifetime major depressive disor-
der (MDD) and lifetime PTSD of 0.50 (Kessler et al., 1995). The
prevalence of comorbid PTSD and depression has been studied
in populations who have experienced a range of traumas. Among
426 participants in the Veterans’ Health Study who met criteria for
PTSD, 82% also met criteria for depression (Hankin et al., 1999).
A study of 62 survivors of motor vehicle accidents with PTSD
reported comorbid depression in 53% of participants (Blanchard
et al., 1998). Similarly, studies of patients hospitalized for physi-
cal trauma have found comorbid depression in 43 (Shalev et al.,
1998) to 55% (O’Donnell et al., 2004) when PTSD was present
3–4 months following the traumatic experience.
The strong association between PTSD and depression sug-
gests a common vulnerability following a traumatic experience
(Breslau et al., 2000). It has been postulated that symptoms of
depression and PTSD may actually represent a singular construct
(O’Donnell et al., 2004), a premise supported by Rasch modeling
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(Elhai et al., 2011). Furthermore, the presence of DSM criterion A
for PTSD diagnosis (i.e., presence of a traumatic event) has been
recently shown to be the only distinguishing symptom between
patients with MDD versus PTSD (Gros et al., 2012). Still, the
overlap between symptoms of PTSD and MDD is not absolute,
and disparate views on the singular construct exist (Grant et al.,
2008). Variation in extent of symptom overlap has been shown in
veterans with PTSD where the specific PTSD symptoms of numb-
ing and dysphoria are more closely related to symptoms of MDD
than other PTSD symptoms of intrusions, avoidance, or arousal
(Gros et al., 2010). Importantly, in terms of etiology and poten-
tial treatment approaches, examination of data from The National
Comorbidity Survey has suggested that PTSD is more often the
primary disorder temporally among people with both PTSD and
depression (Kessler et al., 1995).
Given the high prevalence of comorbid PTSD and depression,
as well as the overlap in symptomatology, the impact of comor-
bid diagnoses should be considered and addressed in treatment.
The co-occurrence of PTSD and MDD is associated with greater
disorder severity (Kessler et al., 2005). In a study of PTSD symp-
toms among veterans at a primary care clinic, those with either
MDD or PTSD (as a singular diagnosis) showed similar levels
of PTSD symptoms on the PCL-C rating scale. Veterans with
both PTSD and MDD had more severe symptoms on all PCL-C
subscales (intrusions, avoidance, dysphoria, numbing, and hyper-
arousal) compared to patients with either disorder alone (Gros
et al., 2012). In addition to its association with greater PTSD symp-
tom severity, comorbid PTSD and depression has been associated
with greater anxiety and lower global functioning (Blanchard et al.,
1998; Momartin et al., 2004; Nixon et al., 2004).
Given greater disorder severity, patients with comorbid diag-
noses have higher health service utilization compared to those
with individual conditions (Kramer et al., 2003), and they also
respond differently to depression treatment regimens. In a study of
low income women, depression was treated with cognitive behav-
ioral therapies (CBT), anti-depressant medications, or community
mental health referral. Through 10 months of treatment, symp-
toms of depression improved less in the women with comorbid
PTSD than in those with singular depression (Green et al., 2006).
Cognitive processing therapy (CPT), which entails 12 sessions
(60–90 min) with practice of skills outside of sessions, has been
reported to be effective in treating comorbid PTSD and depression
among female assault victims (Nishith et al., 2005). Still, nearly all
of the literature on treatment for PTSD and comorbid depression
has arisen in the past few years (Foa et al., 2009), and integrated
treatment is generally recommended.
Notwithstanding the general recommendation for integrated
psychotherapy and pharmacotherapy, results to date suggest that
for individuals with comorbid PTSD and depression, psychother-
apy may be most effective if specifically targeted to PTSD rather
than depression as the primary disorder (e.g., Kessler et al., 1995).
In this realm, evidence-based CBT that are formally endorsed as
first line treatment for PTSD, including by the Veterans Adminis-
tration and Department of Defense, include CPT, exposure-based
therapy (e.g., Prolonged exposure (PE) therapy), and eye move-
ment desensitization and reprocessing (EMDR) (U. S. Department
of Veterans Affairs, 2010). Nonetheless, the above mentioned
therapies have notable limitations including variable efficacy,
frequent dropout, and lengthy treatment regimens. In brief, PE
consists of 10 sessions (approximately 90 min each) with corre-
sponding homework assignments (Foa et al., 2007), dropout rates
of approximately 0–50% (Hembree et al., 2003; Schnurr et al.,
2007; Schottenbauer et al., 2008), and non-response rates between
20 and 67% (Minnen and Hagenaars, 2002; Schottenbauer et al.,
2008). CPT is delivered over 12 sessions lasting 60–90 min with
practice of skills outside of therapy sessions (Resick and Schnicke,
1996), dropout rates of approximately 4–29% (Hembree et al.,
2003; Schottenbauer et al., 2008), and non-response rates between
4 and 48% (Schottenbauer et al., 2008). EMDR consists of 8–
12 weekly 90-min sessions (Friedman, 2003), dropout rates of
approximately 0–36%, and non-response rates between7 and 92%
(Schottenbauer et al., 2008). Hence, no single approach has been
shown to be optimal in terms of delivery time, treatment comple-
tion, and amelioration of PTSD symptoms. In addition, exacerba-
tion rates (i.e., of symptoms) have been reported to range between
13 and 28% for PE and 5 and 10% for CBT (Schottenbauer et al.,
2008).
In light of the above treatment limitations, in particular, sheer
length (and hence cost) of treatment, we report on a new, brief
exposure-based psychotherapy known as Accelerated Resolution
Therapy (ART®) for treatment of PTSD among adults with comor-
bid symptoms of depression. As described below, this therapy
has a strong theoretical basis coupled with limited empirical base
for symptoms of PTSD at large (i.e., irrespective of depressive
symptoms) (Kip et al., 2012). Through the delivery of ART for
trauma-related experiences and distress,we hypothesized clinically
significant reductions in symptoms of both PTSD and depression
in a brief treatment period. We further hypothesized close con-
cordance in treatment response with respect to both PTSD and
depression.
DESCRIPTION OF ART PROTOCOL
The ART protocol uses cognitive behavioral and experiential ther-
apies and was developed to treat both physiological and cognitive
aspects of PTSD, which as a disorder, has been described as a
consequence of failed memory processing when the brain fails to
appropriately consolidate and integrate episodic memory into the
semantic memory system (Stickgold, 2002). The two major com-
ponents of ART that draw from existing evidence-based therapies
for PTSD include the practices of imaginal exposure (reliving)
and imagery rescripting. This is based on the tenets that: (i) most
intrusive memories (i.e., as in PTSD) involve sensory imagery with
visual material being most common (Hackmann, 2011); (ii) PTSD
memories are not well integrated (Conway and Pleydell-Pierce,
2000) and to become less intrusive, need to be integrated with
more positive images (Conway et al., 2004); and (iii) changes in
imagery tend to be accompanied by larger affect shifts than changes
in verbal thought (Holmes et al., 2006).
With respect to the imaginal exposure component prompted
by the ART clinician and retrieved by the patient (whether ver-
balized or not), which in and of itself can bring about cognitive
change in the setting of PTSD (Foa et al., 1995), the ART clinician
oscillates their hand at eye level to the patient (sets of 40 at a time).
In conjunction with these oscillations, the patient performs lateral
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left-right eye movements to facilitate the separation (elimination)
of physiological sensations associated with purposeful recall of
traumatic experiences prior to cognitive intervention. In ART,
this is referred to as “processing” of sensations, and it is believed
to have a calming effect that may promote subsequent limbic
change by shifting from a dominant sympathetic nervous system
mode during imaginal exposure (i.e., “flight or fight” response) to
complementary parasympathetic nervous system dominance.
After exposure to imagined material and processing of physi-
ological sensations for a given traumatic scene, the ART clinician
facilitates imaging rescripting (IR) by asking the patient to come
up with a “solution” to “replace” the distressing images and/or
other senses (but not narrative memory) with positive images. In
ART, this technique is known as Voluntary Image Replacement
(VIR) and it directly parallels IR (“Type A”) in which a preex-
isting negative mental image is transformed into a more benign
image (i.e., negative image to positive image through rescripting)
(Holmes et al., 2007), and which has been successfully used to treat
survivors of traumatic industrial accidents suffering from PTSD
(Grunert et al., 2007).
Despite similarities with EMDR, the most poignant differences
between ART and EMDR are: (i) images: ART uses the VIR tech-
nique to change the actual recall of images and/or other senses
(i.e., from negative to positive), whereas EMDR aims to cognitively
desensitize the patient about their trauma (images); (ii) sensation
processing : ART spends considerably more time processing physi-
ological sensations invoked by exposure to imagined material than
EMDR, and by protocol, dictates that after each “scene-focused”
set of eye movements, the therapist use a corresponding set of
eye movements specifically to process (neutralize) physiological
sensations; (iii) standardization: for each set of eye movements,
ART uses a fixed number (40) to help the patient process, but not
be flooded with information, whereas EMDR changes the num-
ber of eye movements. In addition, ART clinicians use a set of
standard interventions and a fidelity checklist from the ART train-
ing manual, whereas EMDR is less standardized and may require
the therapist to come up with their own “cognitive interweave”
when they get “stuck.” Thus, unlike EMDR, ART is purposely not
free-associative. In addition, the use of the VIR technique in ART
aims to change the images and other sensations associated with
the problematic memory; this differs from PE therapy which aims
to decrease the distress associated with trauma-related thoughts
and prior exposure.
The length of treatment with ART is brief yet variable, and
is based on processing (treating) one or more traumatic scenes
identified as contributing to symptoms of PTSD. This is consis-
tent with the protocol of Arntz and Weertman (1999) who stress
that there is no need for PE, per se, in the treatment of PTSD.
When multiple traumatic scenes exist, approximately three repre-
sentative scenes (i.e., those most contributing to symptoms) may
be processed to eliminate presenting sensations and symptoms,
with an apparent generalizing effect to any remaining scenes of
lesser clinical importance. Thus, treatment is completed when
the scene or representative scenes are processed and the patient
reports significant or full relief from symptoms associated with the
problematic memory. In this study, consenting participants under-
went between one and five sessions of ART (within 3 weeks), each
approximately 60–75 min in length. Individual components used
within each ART session have been described (Kip et al., 2012).
All therapists completed a 42-item ART fidelity checklist after
each treatment session, although, there was no recording of treat-
ment sessions or independent verification of protocol-compliant
delivery of ART.
MATERIALS AND METHODS
ETHICS STATEMENT
The study protocol was approved by the Institutional Review
Board at University of South Florida (USF) and all participants
provided written informed consent.
SCREENING AND ENROLLMENT
The present study is a subgroup analysis derived from a federally
funded prospective cohort treatment study of adults with symp-
toms of PTSD initiated at the USF in 2011 (Kip et al., 2012).
Participants, which included both veterans and civilians, were
recruited through caseload referrals from licensed mental health
therapists in the study area, flyers and brochures, direct meetings
with providers of mental health services, and as a result of local
media coverage. All participants were treated at the USF College
of Nursing and received $20 for completion of self-report ques-
tionnaires (see below) before and after treatment and at 2- and
4-month follow-up.
For screening and potential enrollment, participants completed
three instruments by written self-report as part of an initial intake
assessment. This included the 17-item PCL-C Checklist (Weathers
et al., 1993; Blanchard et al., 1996), a self-developed 9-item ART
Intake Questionnaire, and the 125-item (yes/no) Psychiatric Diag-
nostic Screening Questionnaire (PDSQ). The PDSQ was used to
screen for Axis I disorders and serve as a baseline assessment of
psychopathology. This instrument has been validated against diag-
nostic criteria and interview-derived diagnoses over the course
of 10 years and more than 3,000 administrations (Zimmerman
and Mattia, 2001; Zimmerman and Chelminski, 2006). It can be
quickly hand scored to obtain a total score (which functions as a
global indicator of psychopathology) plus subscale scores for 13
disorders: MDD, generalized anxiety disorder (GAD), panic dis-
order, PTSD, alcohol abuse/dependence, drug abuse/dependence,
psychosis, bulimia/binge-eating disorder, somatization disorder,
obsessive-compulsive disorder, social phobia, hypochondriasis,
and agoraphobia. Participants were given instructions by the study
coordinator and completed these self-report forms in private (no
proxy reports were allowed). Completion of these instruments was
followed by a clinical interview between the potential study sub-
ject and an ART assessment clinician to determine study eligibility.
“Screen fail” participants (i.e., those not meeting enrollment cri-
teria, including those with a T -score >70 indicating need for a
higher level of care) were offered a direct referral for counseling
in the community, or two complimentary sessions at the study
site (and appropriate referral thereafter) of an empirically based
method of psychotherapy.
Full inclusion criteria for the parent study which aimed to treat
symptoms of PTSD (i.e., irrespective of depression), and on which
this subset analysis is based, were: (i) between the age of 21–
60 years inclusive; (ii) symptoms indicative of PTSD, as defined
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as a score of >40 on the PTSD Checklist (range 17–85) – Civilian
version (PCL-C) (Weathers et al., 1993; Blanchard et al., 1996), or
in the absence of a score>40,other documented evidence of symp-
toms, including a high PTSD subscale score and/or endorsement
of specific PTSD item responses on the PDSQ; (iii) ability to
read and speak English to complete survey questions; and (iv)
denial of suicidal and homicidal ideation or intent and no evi-
dence of psychotic behavior or otherwise being in psychological
crisis. Exclusion criteria for the parent study were: (i) brain injury
prohibiting speech, writing, and purposeful actions; (ii) current
suicidal ideation; (iii) major psychiatric disorder (e.g., bipolar
disorder) primary to symptoms of psychological trauma; (iv) cur-
rent treatment for substance abuse; (v) previous diagnosis of eye
movement disorder anticipated to interfere with treatment (e.g.,
amblyopia); and (vi) any medical condition that, in the judgment
of the principal investigator and/or ART therapist, may place the
individual at high risk due to a potential heightened emotional
reaction (e.g., previous heart attack, seizure disorder).
For the present subgroup analysis, additional inclusion criteria
(beyond the parent study, Kip et al., 2012) were selected for analyt-
ical purposes to document evidence of both clinically significant
PTSD and depression, and to approximate clinical diagnoses. This
was based on scores on the PCL-C, Center for Epidemiologic Stud-
ies Depression Scale (CES-D), and subscale scores and individual
item responses from the PDSQ. Specifically, eligibility for the sub-
group analysis from the parent study required presence of all of
the following: (i) PTSD: score of ≥44 on the PCL-C (Blanchard
et al., 1996); score of≥5 on the PTSD subscale of the PDSQ (Zim-
merman and Mattia, 2001); and PDSQ endorsement of item #29
(ever experienced traumatic event) and/or item #30 (ever wit-
nessed traumatic event); (ii) depression: score of ≥9 on the MDD
subscale of the PDSQ (Zimmerman and Mattia, 2001); and score
of ≥16 on the CES-D (McDowell and Newell, 1996).
THERAPIST TRAINING
All therapists underwent intensive training in ART conducted in
person by the developer (Laney Rosenzweig) and lead trainer (Amy
Shuman) and in accordance with the ART training manual. This
included two 8-h days on the theory, principles, and protocol for
conducting ART including intake assessment, intervention tech-
niques, eye movement regimen, challenges and solutions, and clo-
sure techniques. This was followed by directly observed supervised
practice, and then follow-up training and assessment.
DATA COLLECTION
After written consent and clinical screening for determination of
study eligibility, participants completed a demographic and brief
medical history questionnaire provided to them by the research
coordinator. In addition, baseline completion of self-reported
outcome measures by study subjects (in addition to the previ-
ously completed PCL-C) included the following measures: 18-
item Brief Symptom Inventory (BSI) (Derogatis, 2001); 20-item
CES-D (Radloff, 1977); 21-item State-Trait Inventory for Cogni-
tive and Somatic Anxiety (STICSA) (Ree et al., 2008); 26-item
Self-Compassion Scale (SCS) (Neff, 2003); 29-item Aggression
Questionnaire (AQ) (Buss and Perry, 1992); 10-item Alcohol
Use Disorder Identification Test (AUDIT) (Saunders et al., 1993);
32-item Trauma-Related Guilt Inventory (TRGI) (Kubany, 1996);
21-item Post-Traumatic Growth Inventory (PTGI) (Tedeschi and
Calhoun, 1996); and the Pittsburgh Sleep Quality Index (PSQI)
(Buysse et al., 1989). These measures were the same as those
included in the parent study and were selected to assess a wide
range of psychological treatment response and on the basis of
established reliability and validity. The outcome measures were
completed by written self-report by study subjects immediately
before the first ART session, after the final ART session, and at
2- and 4-months post-treatment. Post-treatment evaluations were
completed in person except in rare instances when the subject
could not come to the study site; in these instances, participants
completed and returned assessments via U.S. mail. Occurrence of
adverse events was inquired by the treating therapist prior to each
ART session including the nature and intensity of each event, sub-
sequent treatment actions, and judgment as to whether the event
was causally related to use of ART.
For this subgroup analysis, changes in the PCL-C and CES-
D were considered the primary outcomes, with all other measures
treated as secondary outcomes. The PCL-C is a 17-item self-report
measure of DSM-IV symptoms of PTSD (Weathers et al., 1993;
Blanchard et al., 1996). Respondents rate how much they were
“bothered by that problem in the past month.” Items are rated on
a 5-point scale ranging from 1 (“not at all”) to 5 (“extremely”). A
total score (range 17–85) can be obtained by summing the scores
from each of the 17 items. The CES-D is a 20-item self-report scale
which measures the current level of depressive symptomatology in
the general population, with an emphasis on depressed mood dur-
ing the past week (Radloff, 1977). Items are rated on a 4-point scale
ranging from 0 (rarely or none of the time) to 3 (most or all of the
time) with a possible range of 0–60. The CES-D incorporates the
main symptoms of depression and was derived from five validated
depression scales including the Beck Depression Inventory.
STATISTICAL METHODS
Continuous variables are expressed as mean± standard devia-
tion (SD); categorical variables are presented as percentages. The
analysis is presented sequentially, initially, among the 44 individ-
uals with evidence of clinically significant PTSD and depression,
and second, among the 28 individuals who were eligible for the
study (i.e., based on all inclusion criteria), enrolled, treated, and
with follow-up data. For these 28 subjects, demographic and pre-
senting characteristics were compared by pre-treatment PCL-C
score (classified as below or above the median of 63) and pre-
treatment CES-D score (classified as below or above the median
of 36) using student t tests for continuous variables and Fisher’s
Exact test for categorical variables. Standardized effect sizes for
outcome measures were calculated as: (mean before ART – mean
after ART)/SD of treatment difference scores (Morris and DeShon,
2002) with corresponding 95% confidence intervals calculated.
Within-subject changes on scores from the PCL-C and CES-D were
formally tested by repeated measures analysis of variance specify-
ing an exchangeable correlation structure. Finally, the strength of
association between corresponding pre- to post-ART changes in
PTSD (PCL-C) and depression (CES-D) was estimated by use of
Pearson correlation coefficients. This included changes in total
score on the PCL-C, as well as subscale scores derived from a
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published factor analysis (Asmundsona et al., 2000) with four
factors (subscales) as follows: intrusion/re-experiencing (items
1–5); avoidance (items 6–7); numbing (items 8–12); and hyper-
arousal (items 13–17). Due to multiple comparisons, a two-tailed
p-value of <0.025 was used to define statistical significance for
the primary outcomes (PCL-C and CES-D) and <0.001 for all
secondary outcomes.
RESULTS
From the parent study, a total of 97 individuals were screened,
of whom, 44 (45.4%) met the sub-study definition for comor-
bid PTSD and depression (Figure 1). The 44 individuals with
comorbid PTSD and depression were of similar mean age to the
other 53 screened individuals (40.6 versus 41.1 years) and gen-
der (76.3 versus 78.6%), yet predictably presented with a higher
mean PDSQ-T score (60.2 versus 50.4, p< 0.0001). Of the 44
individuals with comorbid PTSD and depression, 9 (20.5%) did
not meet eligibility (enrollment) criteria in the parent study (e.g.,
due to major concomitant disorder, such a psychosis or suicidal-
ity) or start treatment with ART. Of the 35 subjects enrolled, 4
(11.4%) did not complete treatment, 3 (8.6%) completed treat-
ment but were lost to follow-up, and the remaining 28 (80.0%)
completed treatment and had 2-month and/or 4-month follow-up
data.
PRESENTING PSYCHOLOGICAL STATUS
For the 9 of 44 individuals with clinical evidence of PTSD and
depression, yet who were ineligible or did not start treatment with
ART, concomitant psychopathology was highly prevalent, as deter-
mined from individual subscale scores on the PDSQ (Table 1).
This included scoring at or above the cutpoint for bulimia/binge-
eating disorder (44.4%), obsessive-compulsive disorder (OCD)
(44.4%), panic disorder (66.7%), agoraphobia (75.0%), social
phobia (88.9%), GAD (77.8%), somatization disorder (77.8%),
psychosis (44.4%), and suicidal ideation in the past 2 weeks
(55.6%). For subjects enrolled in the present study (n= 35), the
extent of comorbid psychopathology was lower yet still prevalent
for OCD, panic disorder, agoraphobia, social phobia, GAD, and
somatization disorder.
For the 7 of 35 subjects who did not complete treatment or have
follow-up data, no major adverse events were reported. Compared
to the 28 subjects treated and followed, the 7 subjects without full
treatment and follow-up data were of similar age (33.6± 8.8 versus
40.5± 9.2, p= 0.08), female gender (71.4 versus 78.6%, p= 0.65),
Hispanic ethnicity (33.3 versus 35.7%, p= 1.0), having had trau-
matic memories for ≥11 years (71.4 versus 82.1%, p= 0.61) and
prior treatment for PTSD (71.4 versus 75.0%, p= 1.0). How-
ever, the 7 non-completers were less likely to be married than the
28 completers (14.3 versus 60.7%, p= 0.04). For the 28 subjects
treated and followed, the mean PDSQ-T score was 59.8± 7.3 with
mean scores on the PCL-C (62.5± 8.8) and CES-D (35.1± 8.8)
approximately two SDs above established cutpoints that are sug-
gestive of a diagnosis of PTSD (Blanchard et al., 1996) and depres-
sion (McDowell and Newell, 1996), respectively. For these subjects,
the mean number of ART sessions was 3.7± 1.1 (range 1–5).
DEMOGRAPHIC AND PRESENTING CHARACTERISTICS
The mean age of the 28 treated and followed subjects was
40.5± 9.2 with 79% of female gender, 93% of Caucasian race,
and 36% of Hispanic ethnicity (Table 2). Eighty-two percent had
existing traumatic memories for≥11 years and three-quarters had
received prior mental health treatment for PTSD. When evaluating
presenting characteristics by PCL-C scores below (n= 15) versus
above (n= 13) the median (scores of 45–63 versus 64–81), the
prevalence of higher PCL-scores was non-significantly related to
male gender, having a history of hypertension, and having a history
of neurological problems. When evaluating presenting charac-
teristics by CES-D scores below (n= 15) versus above (n= 13)
the median (scores of 18–36 versus 37–48), the prevalence of
higher CES-D scores was associated with male gender (p= 0.005),
and being unemployed (p= 0.03), and non-significantly related
to having a history of head trauma (p= 0.09). Medication use
at study entry (data not shown) was highly variable, with 43%
FIGURE 1 | Flow diagram of screening, enrollment, and treatment completion of study participants.
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Table 1 | Psychological status of screened consenting individuals with evidence of clinically significant PTSD and depression.
Psychological measure Ineligible/not treateda
(n=9)
Enrolled; no follow-upb
(n=7)
Treated; followedc
(n=28)
Subscale of PDSQ (% meeting cutoff score)d
Bulimia/binge-eating disorder (10/7) 44.4 14.3 25.0
Obsessive-compulsive disorder (7/1) 44.4 71.4 64.3
Panic disorder (8/4) 66.7 28.6 57.1
Psychosis (6/1) 44.4 42.9 42.9
Psychosis (6/2)e 11.1 14.3 10.7
Agoraphobia (11/4) 75.0 42.9 59.3
Social phobia (15/4) 88.9 71.4 89.3
Alcohol abuse/dependence (6/1) 11.1 0.0 25.0
Drug abuse/dependence (6/1) 22.2 0.0 25.0
Generalized anxiety disorder (10/7) 77.8 85.7 71.4
Somatization disorder (5/2) 77.8 57.1 57.1
Hypochondriasis (5/1) 33.3 71.4 46.4
Suicidal ideation in past 2 weeksf 55.6 42.9 28.6
PDSQ-T score (mean±SD) 64.0±6.8 57.0±6.6 59.8±7.3
PCL-C score (mean±SD) 70.2±6.3 66.4±7.1 62.5±8.8
CES-D score (mean±SD) 33.6±8.7 40.3±7.0 35.1±8.8
aReasons included psychosis (n=3), suicidality (n=1), current substance abuse (n= 1), medically high risk (n=1), and did not start treatment (n= 3). bFour participants
started yet did not complete treatment and three participants completed treatment but did not have follow-up. cCompleted treatment and had 2- and/or 4-month
follow-up assessment. dParentheses include number of subscale items/number required to meet cutoff score. eModified to require endorsement of two items on
the PDSQ. fItems 20 and 21 on the PDSQ: during the past 2 weeks; did you seriously consider taking your life? (Item #20); did you think about a specific way to take
your life? (Item #21).
Table 2 | Demographic and presenting characteristics of study subjects.
Characteristic All subjects (n=28) PCL-C score at study entry* CES-D score at study entry*
45 to 63
(n=15)
64 to 81
(n=13)
p-Value 18 to 36
(n=15)
37 to 48
(n=13)
p-Value
Age in years (mean±SD) 40.5±9.2 39.9±8.1 41.2±10.7 0.73 39.9±8.2 41.2±10.6 0.74
Female (%) 78.6 93.3 61.5 0.07 100.0 53.9 0.005
Caucasian race (%)a 92.9 93.3 92.3 1.0 93.3 92.3 1.0
Hispanic ethnicity (%) 35.7 46.7 23.1 0.25 40.0 30.8 0.71
Education (%) 0.78 0.78
High school or less 39.3 33.3 46.2 40.0 38.5
Some college 25.0 26.7 23.1 20.0 30.8
College degree 35.7 40.0 30.8 40.0 30.8
Married (%) 60.7 73.3 46.2 0.25 60.0 61.5 1.0
Unemployed (%) 53.6 46.7 61.5 0.48 33.3 76.9 0.03
History of hypertension (%) 10.7 0.0 23.1 0.09 6.7 15.4 0.58
History of diabetes (%) 7.1 13.3 0.0 0.48 13.3 0.0 0.48
History of head trauma (%) 10.7 6.7 15.4 0.58 0.0 23.1 0.09
History of neurological problems (%) 17.9 6.7 30.8 0.15 20.0 15.4 1.0
Five or more traumatic memories (%) 53.6 66.7 38.5 0.25 66.7 38.5 0.25
Traumatic memories ≥11 years (%) 82.1 86.7 76.9 0.64 86.7 76.9 0.64
Guilt associated with memories (%) 89.3 86.7 92.3 1.0 86.7 92.3 1.0
Prior PTSD mental health treatment (%) 75.0 86.7 61.5 0.20 80.0 69.2 0.67
Currently on disability for PTSD or other
mental health condition (%)
18.5 26.7 8.3 0.34 20.0 16.7 1.0
*Of 13 subjects with PCL-C score ≥64, 10 (76.9%) had a CES-D score ≥37; of 13 subjects with CES-D score ≥37, 10 (76.9%) had a PCL-C score ≥64; p=0.007.
aNon-Caucasian: African American (n= 1) and American Indian (n=1).
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of subjects taking anti-anxiety medications, 32% taking anti-
depressants, and 25% taking both medications. The 28 subjects
were treated by six different therapists, two with doctoral level
training and six with masters level training.
EXAMINATION OF TREATMENT EFFICACY
For the 28 subjects who completed treatment and had follow-
up data, very large, statistically significant treatment effects
were observed for symptoms of PTSD and depression (Table 3;
Figure 2). For the PCL-C, the pre-ART mean (±SD) was 62.5
(8.8) with mean reductions of −29.6 (12.5), −30.1 (13.1), and
−31.4 (14.04) at post-ART, 2-month, and 4-month follow-up,
respectively (p< 0.0001). Compared to pre-ART status, this cor-
responded to standardized effect sizes of 2.37, 2.30, and 3.01,
respectively.
For the CES-D, the pre-ART mean was 35.1 (8.8) with mean
reductions of−20.6 (11.0),−18.1 (11.5), and−15.6 (14.4) at post-
ART, 2-month, and 4-month follow-up, respectively (p< 0.0001).
This corresponded to standardized effect sizes of 1.88, 1.58, and
1.09, respectively. Thus, while there appeared to be a slight attenu-
ation of treatment effect over time for depression (CES-D scores),
effect sizes were still large and suggestive of sustained treatment
response for symptoms of both PTSD and depression.
Treatment with ART showed evidence of clinically and statisti-
cally significant initial and sustained improvements across a range
of psychological symptoms and measures including the BSI (effect
sizes: 2.14, 1.85, 1.75), somatic anxiety (effect sizes: 1.30, 1.27,
1.16), cognitive anxiety (effect sizes: 2.34, 1.24, 1.28), and subscales
of trauma-related growth. Of note, the post-treatment effect sizes
for sleep quality (PSQI) and alcohol use (AUDIT) appeared to be
largest at the 4-month follow-up assessment. The PSQI inquires
about sleep quality over the past month, whereas the AUDIT has
several questions inquiring about alcohol use over the past year
(i.e., potential “delayed” treatment effect due to time period for
which symptoms were reported).
The relationship between change in scores on the PCL-C and
change in scores on the CES-D was modest when considering pre-
ART to initial post-ART assessment (Figure 3; r = 0.45, p= 0.02).
However, much stronger relationships were evident for changes in
PTSD and depression scores from pre-ART to 2-month follow-
up (r = 0.79, p< 0.0001) and pre-ART to 4-month follow-up
(r = 0.76, p= 0.0002). Of note, completion of questions on the
PCL-C is for the past month compared to the past week for ques-
tions on the CES-D. In examining change in PCL-C symptom
subscale scores pre-ART to 2-month follow-up and correspond-
ing changes in CES-D scores, modest to strong relationships
were consistently observed: intrusion/re-experiencing (r = 0.65,
p= 0.0002); avoidance (r = 0.47, p= 0.01); numbing (r = 0.60,
p= 0.0008); hyperarousal (r = 0.70, p< 0.0001). These results are
consistent with the postulate that depression and PTSD may actu-
ally represent a singular construct (O’Donnell et al., 2004; Gros
et al., 2010; Elhai et al., 2011).
ADVERSE EVENTS
One participant reported feeling depressed the day after an ART
session which subsequently resolved. This participant completed
treatment and follow-up. Three additional non-study (treatment)
related events were reported: (i) light headedness with poor
Table 3 | Mean outcome difference scores and effect sizes from pre-treatment to post-treatment, and 2- and 4-month follow-up.
Pre-ART
(n=28)
Mean difference scores (SD) Effect sizes (95% C.I.) p-Value*
Post ART
(n=28)
2-month
(n=28)
4-month
(n=19) Pre/post Pre/2-month Pre/4-month
PTSD checklist (PCL-C) 62.5 (8.8) −29.6 (12.5) −30.1 (13.1) −31.4 (10.4) 2.37 (1.61–3.13) 2.30 (1.57–3.03) 3.01 (1.94–4.08) <0.0001
CES-D (depression) 35.1 (8.8) −20.6 (11.0) −18.1 (11.5) −15.6 (14.4) 1.88 (1.25–2.52) 1.58 (1.04–2.12) 1.09 (0.44–1.74) <0.0001
Brief symptom inventory 39.2 (13.7) −25.5 (11.9) −25.6 (13.9) −24.7 (14.1) 2.14 (1.45–2.83) 1.85 (1.23–2.46) 1.75 (0.98–2.52) <0.0001
STICSA (somatic) 24.0 (7.1) −8.9 (6.8) −7.5 (5.9) −6.3 (5.4) 1.30 (0.76–1.85) 1.27 (0.79–1.74) 1.16 (0.62–1.71) <0.0001
STICSA (cognitive) 28.8 (5.1) −12.3 (5.3) −8.9 (7.2) −9.1 (7.2) 2.34 (1.61–3.07) 1.24 (0.72–1.76) 1.28 (0.68–1.88) <0.0001
Pittsburgh sleep quality 11.4 (4.0) −3.4 (3.5) −3.2 (4.0) −4.4 (4.2) 0.97 (0.57–1.37) 0.80 (0.40–1.20) 1.05 (0.36–1.74) <0.0001
Trauma-related growth
Global guilt 5.4 (2.2) −3.3 (2.6) −3.4 (2.5) −2.5 (2.0) 1.27 (0.70–1.75) 1.37 (0.80–1.94) 1.27 (0.67–1.86) <0.0001
Distress 19.8 (3.2) −10.5 (6.1) −10.2 (5.4) −9.5 (5.4) 1.73 (1.11–2.35) 1.89 (1.24–2.54) 1.76 (1.00–2.51) <0.0001
Guilt cognition 49.6 (17.4) −21.3 (17.4) −22.5 (18.5) −20.9 (15.9) 1.23 (0.70–1.75) 1.22 (0.69–1.74) 1.32 (0.67–1.96) <0.0001
Post-traumatic growth
Relation to others 11.6 (7.0) 6.6 (6.0) 3.7 (6.0) 3.8 (6.6) 1.10 (0.65–1.56) 0.62 (0.25–0.99) 0.58 (0.07–1.10) <0.0001
New possibilities 12.8 (6.2) 6.3 (5.6) 3.0 (6.1) 4.1 (6.7) 1.12 (0.65–1.60) 0.50 (0.14–0.86) 0.61 (0.00–1.22) <0.0001
Personal strength 7.9 (5.4) 5.3 (7.7) 4.3 (3.8) 2.7 (4.3) 0.91 (0.46–1.36) 1.13 (0.73–1.53) 0.64 (0.23–1.05) <0.0001
Spiritual change 5.4 (2.9) 2.1 (3.1) 0.9 (3.7) 1.8 (2.7) 0.69 (0.23–1.15) 0.24 (−0.22–0.71) 0.67 (0.18–1.16) 0.08
Appreciation-life 7.1 (4.5) 3.6 (4.7) 2.0 (4.5) 2.9 (2.9) 0.77 (0.30–1.23) 0.45 (0.03–0.88) 1.00 (0.55–1.45) 0.01
Self-compassion scale 60.5 (14.7) 20.1 (20.5) 17.1 (19.5) 13.6 (17.0) 0.98 (0.52–1.44) 0.88 (0.44–1.31) 0.80 (0.35–1.25) <0.0001
Aggression questionnaire 81.9 (20.4) −15.9 (14.0) −13.9 (16.2) −16.8 (16.9) 1.14 (0.74–1.54) 0.86 (0.49–1.23) 0.99 (0.51–1.48) <0.0001
Alcohol use (AUDIT) 2.6 (2.7) −0.2 (2.1) −0.8 (2.6) −0.7 (1.5) 0.11 (−0.20–0.43) 0.31 (−0.11–0.72) 0.47 (0.11–0.83) 0.03
*Based on repeated measures analysis of variance.
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FIGURE 2 | Distribution of self-report scores on the 17-item PCL-C
(left side: possible range of 17–85) and 20-item CES-D (right side:
possible range of 0–60) at baseline, post-treatment, and 2- and
4-month follow-up. The rectangles depict the interquartile range; the
lower and upper ends of vertical lines depict the fifth and ninety-fifth
percentiles, respectively.
FIGURE 3 | Plots of change in PCL-C scores (x -axis) and change in CES-D scores (y -axis). The plots are presented as changes from pre-ART to post-ART
(left side); pre-ART to 2-month follow-up (middle); and pre-ART to 4-month follow-up (right side). Pearson correlation coefficients are listed.
balance and memory; (ii) headache at the time of the 2-month
follow-up due to having five teeth pulled; and (iii) delayed ability to
complete 2-month follow-up questionnaires due to a car accident.
SENSITIVITY ANALYSIS
Of the 35 participants enrolled, 7 (20%) did not complete treat-
ment (n= 4) or completed treatment yet without follow-up
(n= 3), thereby representing a potential source of bias. For the
PCL-C, a reduction of ≥10 points from baseline assessment
has been defined to represent “reliable” and “clinically meaning-
ful” change (Monson et al., 2008). For the 28 participants with
complete data, 26 (92.9%) achieved this metric; assuming the
worst case scenario whereby the remaining 7 participants failed
to respond, this would result in a minimum response rate of
74.3% for reliable and clinically meaningful change in symp-
toms on PTSD. For the CES-D, a reduction of ≥5 points from
the baseline assessment has been defined to represent reliable and
clinically meaningful change (Jacobson and Truax, 1992). For par-
ticipants with complete data,89.3% achieved this metric; assuming
the worst case scenario whereby the remaining seven participants
failed to respond, this would result in a minimum response rate of
71.4% for meaningful change in symptoms of depression.
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DISCUSSION
In this uncontrolled prospective cohort study of adults with
comorbid symptoms of PTSD and depression, treatment with ART
was associated with large, concomitant reductions in symptom
scores. These effects were observed immediately post-treatment
(effect sizes of 2.37 and 1.88) and at 2-month (effect sizes of
2.30 and 1.58), and 4-month follow-up (effect sizes of 3.01 and
1.09). Clinically, results were achieved with a mean of 3.7 ART
sessions. Among current first line evidence-based treatments for
PTSD (irrespective of comorbid depression), CPT entails 12 treat-
ment sessions (Resick and Schnicke, 1996), PE therapy typically
requires 8–15 treatment sessions (Foa and Rothbaum, 1998), and
eye movement and desensitization (Chemtob et al., 2000; Shapiro,
2001) is an 8-phase program that entails 5–15 treatment sessions.
To address overall length of treatment, shorter psychotherapies
have been investigated, particularly during the acute phase of
PTSD, and with limited empirical evidence of benefit (Sijbrandij
et al., 2007; Rothbaum et al., 2008). Given the brevity of ART,
application to comorbid symptoms of PTSD and depression, and
large effects observed, these data provide a rationale for mecha-
nistic studies and formal comparative effectiveness studies of ART
versus established evidence-based psychotherapies.
POSSIBLE TREATMENT EFFECT MECHANISMS
Whereas ART (developed in 2008) is an emerging new therapy
with a limited empirical evidence base to date (Kip et al., 2012),
multiple explanations may explain, at least in part, the appar-
ent clinically meaningful treatment effects of ART on reducing
comorbid symptoms of PTSD and depression, as well as the close
concordance between post-treatment changes in these symptoms.
At the broadest level, these explanations can be classified distinctly
(i.e., not by relative order of importance) as diagnosis-based,
temporal-sequencing, and therapeutic (mechanistic)-based.
First, among trauma-exposed individuals, it has been shown
empirically that PTSD and MDD symptom items may represent
an underlying dimension, rather than two separate dimensions
(Gros et al., 2010). Gros et al. (2012) recently reported that patients
classified as having either PTSD or MDD (but not both) on the
basis of the Clinician Administered PTSD Scale (CAPS) (Blake
et al., 1995) and Mini International Neuropsychiatric Interview
(MINI) (Sheehan et al., 1998) had comparable PTSD symptom
levels, as derived from the PCL-C and Trauma Assessment for
Adults Questionnaire. Thus, it is not unexpected that changes
in symptoms of both PTSD and depression after treatment (i.e.,
with ART) would be highly correlated. These data also support
the notion of broader use of transdiagnostic treatments that
emphasize the commonality of emotional disorders and highly
overlapping symptoms (Ellard et al., 2010).
Second, PTSD may precede depression (Breslau et al., 1997,
2000), and vice versa, depression may precede PTSD (Shalev
et al., 1998; Erickson et al., 2001). King et al. (2009) prospec-
tively studied adult emergency room admittees who experienced a
traumatic event and provided evidence for both directions. How-
ever, when PTSD was antecedent to depression, the strongest
relationship occurred for PTSD symptom clusters of intrusion
and hyperarousal, and little to no predictive value of the PTSD
symptom clusters of avoidance and numbing. By design, our
study recruited and enrolled participants on the basis of present-
ing PTSD symptomatology, and ART was initially conceived and
developed for the treatment of psychological trauma. In spite of
this, we cannot ascertain the extent to which PTSD preceded symp-
toms of depression in our study sample. Nonetheless, we observed
strong pre/post-treatment relationships (improvements) between
all PTSD symptom clusters and depression. Therefore, at least with
respect to treatment with ART, reductions in depressive symp-
toms appear to occur in close concordance with reductions in all
symptoms of PTSD.
Third, in addition to use of the VIR technique in ART
for imagery rescripting, it is possible that lateral left-right eye
movements may foster inter-hemispheric communication in a
“problem-solving” manner similar to that used during rapid eye
movement (REM) sleep. A hallmark of PTSD is disrupted sleep
with intrusive, terrifying dreams and defective processing of emo-
tionally laden memories (Foa and Kozak, 1986). Similarly, sleep
structure in depression, in comparison to healthy individuals, is
characterized by reduced slow-wave sleep (SWS), shortened REM
sleep latency, and redistribution of REM sleep throughout the
night (Coble et al., 1981; Kupfer et al., 1984). Moreover, both the
PCL-C and CES-D have specific sleep-impairment items. Theo-
retically, if the sets of eye movements used with ART “simulate”
some aspects of REM sleep, this in turn may be expected to result
in more selective and efficient processing of emotional memories
(Wagner et al., 2001) with therapeutic benefit for both PTSD and
depression.
A hypothesis alternative yet similar to imagery rescripting to
address how ART appears to produce salutary effects on treat-
ment outcome is that ART interacts with a process known as
“memory reconsolidation.” Extensive research indicates that a
fear-provoking memory is first stored, i.e., consolidated, and then
after it is retrieved at a later time it must be actively stored once
again, or reconsolidated (Nader et al., 2000; Nader and Hardt,
2009). Preclinical (Nader et al., 2000; Duvarci et al., 2005; Pit-
man, 2011; Finnie and Nader, 2012) and clinical (Brunet et al.,
2008, 2011; Schwabe et al., 2012) studies have shown that during
the reconsolidation process, a memory is vulnerable to modifi-
cation by amnestic or anxiolytic agents administered in conjunc-
tion with traumatic memory reactivation, i.e., during exposure
therapy. Therefore, pharmacological blockade of reconsolidation
has become a novel strategy in the treatment of PTSD (Debiec
and LeDoux, 2006; de Quervain and Margraf, 2008; Donovan,
2010; Pitman, 2011). The therapeutic benefit of ART for both
PTSD and depression may be related to findings in research
on reconsolidation. In theory, the interaction of imaginal expo-
sure that occurs in conjunction with the critical elements of
ART, i.e., eye movements, reduced physiological and affective
responses during imaginal exposure, and imagery rescripting,
generates a reconsolidated hybrid memory, which includes non-
trauma (ART-specific) components. The hybrid memory, there-
fore, upon subsequent retrieval, may be less traumatic to the
patient.
STRENGTHS AND LIMITATIONS
There are several strengths to our study. All therapists were for-
mally certified in ART using a standard protocol, recruited from
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the community, and possessed varying educational backgrounds
at the masters and doctoral level. This provides some degree of
generalizability across therapists, as well as standardization of the
training and delivery of ART. However, despite completing a stan-
dardized 42-item ART fidelity checklist after each treatment ses-
sion, there was no independent verification of delivery of ART by
the six individual clinicians. Thus, this study cannot confirm that
all clinicians delivered ART in full compliance with the treatment
protocol. Second, the self-report outcome measures utilized are
reliable and valid instruments. Third, neither the founder of ART
(Laney Rosenzweig) nor lead trainer (Amy Shuman) performed
any cases or participated in data collection or analysis.
Despite these strengths, there are limitations. First and fore-
most, there was no control group to compare the results achieved
with ART versus therapist attention alone. This uncontrolled
cohort study design is typical for an early stage evolving ther-
apy such as ART, but can provide suggestion of effectiveness.
Second, assessment of treatment efficacy of ART for comor-
bid PTSD and depression is based on changes in symptoma-
tology. Thus, we cannot directly infer from our data that use
of ART results in change in DSM-derived diagnoses, includ-
ing PTSD and depression. Having said this, the multiple symp-
tom criteria used in this analysis (see Materials and Methods)
to define clinically significant PTSD and depression provide
some assurance of true diagnoses in the majority of partic-
ipants. Third, subjects presented with high levels of sympto-
matology beyond PTSD and depression (e.g., somatization and
OCD) which limits generalizability of study results to confined
presentations of PTSD and depression, yet, is also characteris-
tic of multiple dimension comorbidity frequently seen in clin-
ical practice. Finally, the sample size of 28 subjects is modest,
predominantly female, and 9 did not complete the 4-month
follow-up assessment. These characteristics limit broad general-
izability.
CONCLUSION
From this uncontrolled prospective cohort study, ART appears to
be a brief, safe, and effective treatment for adults with clinically
significant comorbid symptoms of PTSD and depression. Future
mechanistic and controlled studies with ART are warranted, par-
ticularly given its much shorter treatment protocol in comparison
to current evidence-based therapies.
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